Sinorda and HuaDong Pharma Enter into Commercialization Partnership for Linaprazan Glurate, a novel gastric acid inhibitor

Guiyang, China – December 7 –  Guizhou Sinorda Biotech Co., Ltd., its wholly-owned subsidiary Shanghai Sinorda Medicine Tech. Co., Ltd., and Jiangsu Sinorda Biopharma Co., Ltd. (collectively, "Sinorda") announced that has entered into an exclusive commercialization agreement with Huadong Medicine (Hangzhou) Co., Ltd., which is wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZSE: 000963, "HuaDong Pharma") , for Mainland China for Sinorda's product Linaprazan Glurate Capsules and other dosage forms.
 

Linaprazan Glurate is a novel Potassium-competitive Acid Blocker (PCAB) drug co-developed by Sinorda and Cinclus Pharma for treating gastric acid related diseases. The drug has currently been approved in China for the treatment of erosive esophagitis and has been successfully included in the 2025 National Reimbursement Drug List (NRDL).
 

According to the agreement, Sinorda, as the Marketing Authorization Holder (MAH), will be responsible for the research, development, registration, production, and supply of Linaprazan. Following the signing and effectiveness of the agreement, Sinorda will receive an upfront payment and is eligible for additional milestone payments. HuaDong Pharma will be responsible for the commercialization and promotion of Linaprazan Glurate within Mainland China.
 

Mr. Hu Pingsheng, Chairman and CEO of Sinorda, stated: "Linaprazan Capsules represent a new class of anti-acid agents (PCAB) and are a Class 1.1 innovative drug in China, addressing unmet clinical needs in gastric acid rated diseases. China is the first country Linaprazan Glurate launched after over a decade of development. HuaDong Pharma is a leading domestic pharmaceutical in China and we believe this collaboration will enable rapid commercialization, benefiting more patients in China. Furthermore, the partnership with HuaDong will positively and significantly impact the global commercialization of Linaprazan Glurate."
 

Mr. Liang Lü, Chairman and General Manager of HuaDong Pharma, commented: "We are very pleased to enter into this strategic collaboration with Sinorda. The digestive disease therapeutic area is one of our core businesses where we have long-standing expertise and a significant market presence. This partnership for Linaprazan is expected to create strong synergies with our existing product portfolio, further strengthening our pipeline in the treatment of digestive system diseases. Leveraging our nationwide marketing network and extensive experience in promoting digestive disease treatments, we will fully commit to driving the market penetration of this innovative product, allowing more patients to benefit from it."
 

About Linaprazan Glurate

Linaprazan Glurate Capsules and other dosage forms belong to a new generation of Potassium-competitive Acid Blocker (PCAB) drugs. Its oral formulation has been approved and launched in China for Gastroesophageal Reflux Disease (GERD). Additionally, Phase III clinical trials are underway for indications including duodenal ulcer and Helicobacter pylori infection eradication. The drug has been successfully included in the 2025 NRDL for the GERD indication.
 

About Sinorda

Guizhou Sinorda Biotech Co., Ltd., founded in 2014, is a company in commercial stage focusing on the R&D of innovative drugs for gastrointestinal diseases, cancer immunotherapy, and autoimmune diseases. Sinorda has several technology platforms and an experienced international R&D team with successful track records in filing innovative products in China, Europe, and the US. Through extensive collaboration with domestic and international pharmaceutical companies and research institutions, the company is rapidly developing and aims to become a sustainable company in future.
 

About HuaDong Pharma

Huadong Medicine Co., Ltd. (SZSE: 000963), founded in 1993 and headquartered in Hangzhou, Zhejiang Province, adheres to the corporate philosophy of "Science-based, Patient-centered." After more than 30 years of development, its business covers the entire pharmaceutical industry chain, comprising four major segments: Pharmaceutical Manufacturing, Pharmaceutical Commerce, Medical Aesthetics, and Industrial Microbiology. It has grown into a large, comprehensive listed pharmaceutical company integrating innovative R&D, manufacturing, and distribution. In 2024, the company reported revenue of RMB 41.906 billion, employs over 10,000 staff, and possesses extensive commercial coverage and marketing capabilities.